Provectus Biopharmaceuticals, Inc. Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc.

PVCT

Rank in Stocks #26783
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm... Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to pioneering immunotherapy treatments. These therapies are grounded in its proprietary halogenated xanthene platform. Among its key developments is PV-10, an experimental autolytic cancer immunotherapy. This treatment is being explored for a range of adult solid tumor malignancies, encompassing melanoma and various gastrointestinal cancers (such as hepatocellular carcinoma, metastatic colorectal cancer to the liver, metastatic neuroendocrine tumors to the liver, and metastatic uveal melanoma to the liver). It also targets pediatric solid tumors, including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. Additionally, Provectus is advancing oral formulations of pharmaceutical-grade rose bengal sodium (cGMP RBS) to combat a broad spectrum of conditions. These include adult solid tumors (such as head and neck, breast, testicular, and colorectal cancers), pediatric blood cancers like leukemia, acute respiratory syndromes such as coronavirus, infections caused by multi-drug resistant bacteria (specifically Gram-negative bacteria), and certain ocular conditions, notably infectious keratitis. Furthermore, the company is progressing PH-10, an investigational immuno-dermatology agent designed to address inflammatory skin conditions like psoriasis and atopic dermatitis. Originally established in 2002, the company was initially named Provectus Pharmaceuticals, Inc., before rebranding as Provectus Biopharmaceuticals, Inc. in December 2013. Its operations are headquartered in Knoxville, Tennessee.
Share Price
$0.0425
Last synced: 2026-11-13
Market Cap
$17.86M
Change (1 day)
0.00%
Change (1 year)
-30.33%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Provectus Biopharmaceuticals, Inc. (PVCT)

Category

Healthcare
Operating Margin for Provectus Biopharmaceuticals, Inc. (PVCT)
Operating Margin as of November 2026 TTM: 0.00%
According to Provectus Biopharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of -1,441.28%.
Operating Margin history for Provectus Biopharmaceuticals, Inc. from 2000 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 0.00% -100.00%
2025 -1,441.28% 124.92%
2024 -640.81% 23.19%
2023 -520.16% 50.08%
2022 -346.60% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% -100.00%
2014 -302.37% 0.00%
2013 0.00% 0.00%
2012 0.00% -100.00%
2011 -0.22% 0.00%
2010 0.00% 0.00%
2009 0.00% 0.00%
2008 0.00% 0.00%
2007 0.00% -100.00%
2006 -527,923.98% 504.08%
2005 -87,392.90% 666.23%
2004 -11,405.52% 0.00%
2003 0.00% 0.00%
2002 0.00% 0.00%
2001 0.00% -100.00%
2000 -1,149,900.00% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -
US
33.87% -
US
-116.04% -
US
25.57% -
AU
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Provectus Biopharmaceuticals, Inc.'s operating margin

What was Provectus Biopharmaceuticals, Inc.'s operating margin in 2025?

In 2025, Provectus Biopharmaceuticals, Inc.'s operating margin was -1,441.28%, compared with -640.81% in 2024.

How has Provectus Biopharmaceuticals, Inc.'s operating margin changed since 2020?

From 2020 to 2025, Provectus Biopharmaceuticals, Inc.'s operating margin was highest in 2021 (0.00%) and lowest in 2025 (-1,441.28%).

How does Provectus Biopharmaceuticals, Inc.'s operating margin compare with similar companies?

Provectus Biopharmaceuticals, Inc.'s operating margin (0.00%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.